From Screening to Strategy: Targeted Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Prediction After Endoscopic Retrograde Cholangiopancreatography (ERCP)

从筛查到策略:内镜逆行胰胆管造影术(ERCP)后靶向预测耐碳青霉烯类肠杆菌科细菌(CRE)感染

阅读:2

Abstract

BACKGROUND: Invariably, patients can be exposed to Carbapenem-resistant Enterobacteriaceae (CRE) through contaminated device during Endoscopic retrograde cholangiopancreatography (ERCP). We aimed to identify the risk factors and establish a model for predicting subsequent CRE infections in patients with CRE-positive bile screening after ERCP. METHODS: Patients underwent ERCP were performed with bile active screening of CRE. Medical records were reviewed to identify patient demographics, comorbidities, microbiology and antimicrobial treatments. The results were grouped according to the occurrence of subsequent CRE infection, and the patients were divided into two groups: a CRE infection group and a non-CRE infection group. The diagnosis for CRE infection was confirmed by more than 2 physicians. Logistic regression methods were used to determine the risk factors for CRE infections. The risk prediction model was constructed by integrating the clinical data and the result of logistic regression, by a nomogram and forest plot. Finally, goodness of fit of the final model was tested using the likelihood ratio test. RESULTS: Central venous catheterization (OR=11.32; 95% CI 1.15-40.62), cholecystitis (OR=3.82; 95% CI 1.12-13.01), malignancy (OR=4.33; 95% CI 1.41-13.35) and the antimicrobial drug use (OR=1.08; 95% CI 1.03-1.14) were considered as highly relevant risk factors for subsequent CRE infections in bile active screening positive patients. The goodness of fit test indicated that the model was well-calibrated for both groups. CONCLUSION: A targeted active screening in bile samples can be beneficial for patients with high risk factors of CRE infections. The nomogram developed in this study can help clinicians accurately predict the possibility of patients with subsequent CRE infections after ERCP, so as to facilitate more precise individualized treatment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。